Cell free fetal dna | prenatal screening through foetal DNA | Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Cell-free fetal DNA

Cell-Free Fetal DNA Screening Offers Greater Accuracy

Non-invasive prenatal testing (NIPT) is an innovative form of genetic screening allowing for early detection of the most common fetal aneuploidies in at-risk pregnant women, including Patau Syndrome (trisomy 13), Edwards' Syndrome (trisomy 18), and Down Syndrome (trisomy 21). The cell-free fetal DNA testing method offers greater accuracy than triple tests and quad tests, since the latter analyse maternal hormone levels rather than DNA markers in the blood. Healthcare providers now have the option of prescribing non-invasive cell-free fetal DNA tests that rapidly screen cell-free fetal and maternal DNA and detect anomalies. In many cases, these allow patients to avoid invasive sampling, leading to improved maternal and child health outcomes.

The cell-free fetal DNA testing kit developed by Eurofins Biomnis presents zero risk to the fetus and allows healthcare providers, in many cases, to offer patients early reassurance. Moreover, the test, which additionally allows for analysis of sex aneuploidies, has greater sensitivity and specificity when compared to serum marker screening, yielding unusual accuracy. The non-invasive cell-free fetal DNA testing kit is remarkably sensitive and specific, and is classified as a screening option for women at heightened risk of trisomy 13 (Patau Syndrome), as well as trisomies 18 and 21. If one or more pathologies is suspected, an invasive procedure such as amniocentesis is administered to confirm diagnosis.

Prescribing an NIPT for the prenatal screening of birth defectsoffers reliable initial risk assessment for common abnormalities. With detection rates exceeding 99%, cell-free fetal DNA screening is generally recommended for mothers over the age of 38 with risks greater than 1 in 1,000 according to serum markers. A positive result indicates a strong suspicion that anomalies relating to one or more genetic conditions are present. Available starting at 10 weeks of pregnancy, the test provides remarkably accurate cell-free fetal DNA screening from the first trimester of pregnancy. EurofinsBiomnis follows the international recommendations of the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM).

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%